A randomized comparison of the effect of empagliflozin for endothelial function in type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000024001
- Lead Sponsor
- Chigasaki Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with severe renal dysfunction (eGFR < 45 ml/min/1.73m2) 2.Patients with severe liver dysfunction 3.Patients have history of cardiovascular disease and cerebral infarction within 24 weeks 4.Patients taking steroid 5.Patients with cancer 6.Patients with severe infection and trauma 7.Patients are pregnant or have possibility of pregnancy 8.Patients have an allergy to empagliflozin, glimepiride, glargine and metformin 9.Patients considered inappropriate to participate in this study by the doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of FMD% with additional treatment before and after 12 weeks
- Secondary Outcome Measures
Name Time Method 1.Change of them with additional treatment before and after 12 weeks Fasting plasma glucose Postprandial plasma glucose HbA1c GA Fasting CPR Renal function Urinary albumin L-FABP UA Body weight Waist BMI Blood pressure Heart rate Lipid profile(TC, TG, HDL-C, LDL-C) Body domposition(Body fluid volume, Skeletal muscle mass, Total fat mass) 2.Adverese event